{"id":459,"date":"2025-07-16T07:28:27","date_gmt":"2025-07-15T22:28:27","guid":{"rendered":"https:\/\/hara-heart.com\/blog\/?p=459"},"modified":"2025-07-16T07:30:27","modified_gmt":"2025-07-15T22:30:27","slug":"%e9%99%a2%e9%95%b7%e3%81%8c%e7%ad%86%e9%a0%ad%e8%91%97%e8%80%85%e3%82%92%e5%8b%99%e3%82%81%e3%81%9f%e6%96%b0%e3%81%97%e3%81%84%e8%ab%96%e6%96%87%e3%81%8cjacc-cardiovascular-interventions%e3%81%ab","status":"publish","type":"post","link":"https:\/\/hara-heart.com\/blog\/archives\/459\/","title":{"rendered":"\u9662\u9577\u304c\u7b46\u982d\u8457\u8005\u3092\u52d9\u3081\u305f\u65b0\u3057\u3044\u8ad6\u6587\u304cJACC: Cardiovascular Interventions\u306b\u63b2\u8f09\u3055\u308c\u307e\u3057\u305f\uff01"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n
\u3053\u306e\u305f\u3073\u3001\u9662\u9577\u3000\u539f\u5f18\u5178\u304c\u7b46\u982d\u8457\u8005\u3092\u52d9\u3081\u305f\u8ad6\u6587\u304c\u3001\u7c73\u56fd\u5fc3\u81d3\u75c5\u5b66\u4f1a\uff08ACC\uff09\u306e\u516c\u5f0f\u30b8\u30e3\u30fc\u30ca\u30eb\u306e\u4e00\u3064\u3067\u3042\u308bJACC: Cardiovascular Interventions<\/mark><\/strong>\u306b\u63b2\u8f09\u3055\u308c\u307e\u3057\u305f\u3002(1)
https:\/\/www.jacc.org\/doi\/10.1016\/j.jcin.2025.03.027<\/a>


\u8ad6\u6587\u30bf\u30a4\u30c8\u30eb\u306f

\u300cWho Is the True High-Bleeding-Risk Patient?\uff08\u8ab0\u304c\u672c\u5f53\u306e\u9ad8\u51fa\u8840\u30ea\u30b9\u30af\u60a3\u8005\u304b\uff1f\uff09\u300d<\/mark><\/strong>

\u3067\u3059\u3002


\u3053\u306e\u8ad6\u6587\u3067\u306f\u3001\u51a0\u52d5\u8108\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u5f8c\u306b\u51fa\u8840\u30ea\u30b9\u30af\u304c\u9ad8\u3044\u3068\u3055\u308c\u308b\u60a3\u8005\u7fa4\u306e\u5b9a\u7fa9\u3068\u30ea\u30b9\u30af\u4e88\u6e2c\u306e\u3042\u308a\u65b9\u306b\u3064\u3044\u3066\u3001\u6700\u65b0\u306e\u77e5\u898b\u3092\u8e0f\u307e\u3048\u305f\u8003\u5bdf\u3092\u884c\u3044\u307e\u3057\u305f\u3002


\u3010\u7814\u7a76\u306e\u80cc\u666f\u3068\u76ee\u7684\u3011<\/mark><\/strong>

\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u5f8c\u306e\u60a3\u8005\u3055\u3093\u3067\u306f\u3001\u6297\u8840\u5c0f\u677f\u85ac\u6cbb\u7642\u304c\u7d9a\u304f\u305f\u3081\u3001\u51fa\u8840\u30ea\u30b9\u30af\u304c\u91cd\u8981\u306a\u8ab2\u984c\u3068\u306a\u308a\u307e\u3059\u3002
\u8fd1\u5e74\u3001ARC-HBR\uff08Academic Research Consortium for High Bleeding Risk\uff09 \u3084 PRECISE-DAPT \u306a\u3069\u3001\u51fa\u8840\u30ea\u30b9\u30af\u3092\u5224\u5b9a\u3059\u308b\u305f\u3081\u306e\u6307\u6a19\u304c\u63d0\u5531\u3055\u308c\u3066\u304d\u307e\u3057\u305f\u304c\u3001\u3053\u308c\u3089\u306e\u6307\u6a19\u306e\u7cbe\u5ea6\u3084\u9069\u7528\u306e\u9650\u754c\u306b\u3064\u3044\u3066\u306f\u3001\u307e\u3060\u8b70\u8ad6\u304c\u7d9a\u3044\u3066\u3044\u307e\u3059\u3002

\u672c\u8ad6\u6587\u3067\u306f\u3001\u9662\u9577\u304c\u7559\u5b66\u3057\u3066\u3044\u305f\u65bd\u8a2d\u306b\u3066\u5b9f\u65bd\u3055\u308c\u305f\u5927\u898f\u6a21\u81e8\u5e8a\u8a66\u9a13 GLOBAL LEADERS\u8a66\u9a13 \u306e\u30c7\u30fc\u30bf\u3092\u7528\u3044\u3001\u65e2\u5b58\u30b9\u30b3\u30a2\u306e\u59a5\u5f53\u6027\u3068\u8ab2\u984c\u3092\u691c\u8a3c\u3057\u307e\u3057\u305f\u3002


\u3010\u4e3b\u306a\u5185\u5bb9\u3068\u7d50\u679c\u3011<\/mark><\/strong>

GLOBAL LEADERS\u8a66\u9a13\u3067\u306f\u3001\u5168\u60a3\u8005\uff0815,968\u540d\uff09\u306e\u3046\u3061\u3001
ARC-HBR\u57fa\u6e96\u3067\u306f12.1%\u3001PRECISE-DAPT\u57fa\u6e96\u3067\u306f16.3%\u304c\u9ad8\u51fa\u8840\u30ea\u30b9\u30af\uff08HBR\uff09\u3068\u5206\u985e\u3055\u308c\u307e\u3057\u305f\u3002

ARC-HBR\u304a\u3088\u3073PRECISE-DAPT\u30b9\u30b3\u30a2\u306f\u3044\u305a\u308c\u3082\u30011\u5e74\u4ee5\u5185\u306e\u91cd\u5927\u306a\u51fa\u8840\uff08BARC type 3-5\uff09\u306e\u4e88\u6e2c\u6027\u80fd\u304c\u5341\u5206\u3068\u306f\u3044\u3048\u305a\u3001\u7279\u306bARC-HBR\u30e2\u30c7\u30eb\u3067\u306f\u51fa\u8840\u30ea\u30b9\u30af\u306e\u904e\u5927\u63a8\u5b9a\u304c\u307f\u3089\u308c\u307e\u3057\u305f\u3002
\u4e00\u65b9\u3001Lim\u3089\u306b\u3088\u308b\u5927\u898f\u6a21\u30ec\u30b8\u30b9\u30c8\u30ea\u7814\u7a76\u3067\u306f\u3001\u5b9f\u969b\u306e\u51fa\u8840\u7387\u304c\u4e88\u6e2c\u5024\uff084%\uff09\u3092\u5927\u304d\u304f\u4e0a\u56de\u308b7.1%\u3067\u3042\u3063\u305f\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u3066\u304a\u308a\u307e\u3059\u3002(2)

\u7814\u7a76\u9593\u3067\u7570\u306a\u308b\u7d50\u679c\u304c\u51fa\u305f\u80cc\u666f\u306b\u306f\u3001

\u30fb\u767b\u9332\u60a3\u8005\u306e\u80cc\u666f\uff08\u4f8b\uff1a\u904e\u53bb\u306e\u5927\u51fa\u8840\u6b74\u306e\u6709\u7121\uff09
\u30fb\u4f7f\u7528\u3055\u308c\u305f\u6297\u8840\u5c0f\u677f\u6cbb\u7642\u30ec\u30b8\u30e1\u30f3\uff08\u4f8b\uff1aP2Y12\u963b\u5bb3\u85ac\u5358\u5264\u7642\u6cd5\u306e\u666e\u53ca\uff09

\u306a\u3069\u306e\u9055\u3044\u304c\u3042\u308b\u3053\u3068\u304c\u6307\u6458\u3057\u3066\u304a\u308a\u307e\u3059\u3002

\u4eca\u5f8c\u306f\u5f93\u6765\u578b\u30b9\u30b3\u30a2\u306b\u983c\u308b\u3060\u3051\u3067\u306a\u304f\u3001\u6a5f\u68b0\u5b66\u7fd2\uff08Machine Learning\uff09 \u3092\u6d3b\u7528\u3059\u308b\u3053\u3068\u3067\u3001\u8907\u96d1\u306a\u975e\u7dda\u5f62\u95a2\u4fc2\u3092\u6349\u3048\u3001\u3055\u3089\u306b\u6cbb\u7642\u30ec\u30b8\u30e1\u30f3\u306e\u5909\u5316\u306b\u3082\u67d4\u8edf\u306b\u5bfe\u5fdc\u3067\u304d\u308b\u3001\u3088\u308a\u7cbe\u5ea6\u306e\u9ad8\u3044\u30ea\u30b9\u30af\u4e88\u6e2c\u30e2\u30c7\u30eb\u306e\u69cb\u7bc9\u304c\u671f\u5f85\u3055\u308c\u308b\u3053\u3068\u3092\u63d0\u8a00\u3057\u307e\u3057\u305f\u3002


\u3010\u6700\u5f8c\u306b\u3011<\/mark><\/strong>

\u672c\u7814\u7a76\u306f\u3001\u51a0\u52d5\u8108\u75be\u60a3\u60a3\u8005\u3055\u3093\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u9078\u629e\u306e\u6700\u9069\u5316\u306b\u8ca2\u732e\u3067\u304d\u308b\u3082\u306e\u3068\u8003\u3048\u3066\u304a\u308a\u307e\u3059\u3002

\u3053\u308c\u307e\u3067\u306b\u3082\u3001\u9662\u9577\u306f\u3001

\u30fb\u6025\u6027\u51a0\u75c7\u5019\u7fa4\uff08ACS\uff09\u60a3\u8005\u306b\u5bfe\u3059\u308b5\u3064\u306e\u30ea\u30b9\u30af\u4e88\u6e2c\u30e2\u30c7\u30eb\u3092\u6bd4\u8f03\u691c\u8a3c\u3002\u6a5f\u68b0\u5b66\u7fd2\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u7528\u3044\u305fPRAISE\u30b9\u30b3\u30a2\u304c\u3001\u6b7b\u4ea1\u30fb\u5fc3\u7b4b\u6897\u585e\u30fb\u51fa\u8840\u306e\u4e88\u6e2c\u306b\u6709\u7528\u3067\u3042\u308b\u3053\u3068\u793a\u3057\u3001\u6a5f\u68b0\u5b66\u7fd2\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u53ef\u80fd\u6027\u3092\u793a\u5506\u3057\u305f\u3002(3)<\/strong>

\u30fbARC-HBR\u57fa\u6e96\u306b\u57fa\u3065\u304d\u9ad8\u51fa\u8840\u30ea\u30b9\u30af\u60a3\u8005\u306b\u304a\u3051\u308b\u51fa\u8840\u3068\u8840\u6813\u306e\u30ea\u30b9\u30af\u30c8\u30ec\u30fc\u30c9\u30aa\u30d5\u3092\u5206\u6790\u3057\u3001\u500b\u5225\u5316\u3055\u308c\u305f\u6297\u8840\u6813\u7642\u6cd5\u306e\u91cd\u8981\u6027\u3092\u793a\u3057\u305f\u3002(4)<\/strong>

\u3068\u3044\u3063\u305f\u3001\u51a0\u52d5\u8108\u75be\u60a3\u60a3\u8005\u3055\u3093\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u9078\u629e\u306e\u6700\u9069\u5316\u3092\u76ee\u6307\u3057\u305f\u7814\u7a76\u306b\u53d6\u308a\u3093\u7d44\u3093\u3067\u304d\u307e\u3057\u305f\u3002


\u4eca\u5f8c\u3082\u3001\u6700\u65b0\u306e\u77e5\u898b\u3092\u81e8\u5e8a\u306b\u9084\u5143\u3057\u3001\u60a3\u8005\u3055\u3093\u4e00\u4eba\u3072\u3068\u308a\u306b\u6700\u9069\u306a\u533b\u7642\u3092\u63d0\u4f9b\u3067\u304d\u308b\u3088\u3046\u52aa\u3081\u3066\u307e\u3044\u308a\u307e\u3059\u3002<\/mark>

\u3054\u8208\u5473\u306e\u3042\u308b\u65b9\u306f\u3001\u305c\u3072\u8ad6\u6587\u672c\u6587<\/a>\u3082\u3054\u89a7\u3044\u305f\u3060\u3051\u307e\u3059\u3068\u5e78\u3044\u3067\u3059\u3002


\u4eca\u5f8c\u3068\u3082\u3001\u5f53\u9662\u3092\u3069\u3046\u305e\u3088\u308d\u3057\u304f\u304a\u9858\u3044\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002



1. Hara H, Tsai TY, Onuma Y, Serruys PW. Who is the true high-bleeding-risk patient? JACC Cardiovasc Interv. 2025;18:1718\u20131719.

2. Lim CE, Simonsson M, Pasternak B, Jernberg T, Edgren G, Ueda P. Discordance and performance of the ARC-HBR and PRECISE-DAPT highbleeding risk definitions after coronary stenting. JACC Cardiovasc Interv.2025;18:637\u2013650.

3. Hara H, O'Leary N, Ono M, Onuma Y, Serruys PW. A comparison of risk prediction models for patients with acute coronary syndromes. EuroIntervention. 2022;17:1-3.

4. Hara H, Ono M, Kawashima H, Onuma Y, Serruys PW. Trade-off betweenbleeding and thrombotic risk in patients with academic research consortiumfor high bleeding risk. JAMA Cardiol. 2021;6:1092\u20131094.
<\/pre>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
\u3053\u306e\u305f\u3073\u3001\u9662\u9577\u3000\u539f\u5f18\u5178\u304c\u7b46\u982d\u8457\u8005\u3092\u52d9\u3081\u305f\u8ad6\u6587\u304c\u3001\u7c73\u56fd\u5fc3\u81d3\u75c5\u5b66\u4f1a\uff08ACC\uff09\u306e\u516c\u5f0f\u30b8\u30e3\u30fc\u30ca\u30eb\u306e\u4e00\u3064\u3067\u3042\u308bJACC: Cardiovascular Interventions\u306b\u63b2\u8f09\u3055\u308c\u307e\u3057\u305f\u3002(1)https:\/\/www.ja […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-459","post","type-post","status-publish","format-standard","category-3"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\n\t\t